The impact of enzyme replacement therapy on the oral health manifestations of hypophosphatasia among children: a scoping review.
Children
Enzyme replacement therapy
Hypophosphatasia
Odontohypophosphatasia
Journal
European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry
ISSN: 1996-9805
Titre abrégé: Eur Arch Paediatr Dent
Pays: England
ID NLM: 101277157
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
16
01
2023
accepted:
22
03
2023
medline:
31
7
2023
pubmed:
11
4
2023
entrez:
10
4
2023
Statut:
ppublish
Résumé
A scoping review to describe the use of enzyme replacement therapy (ERT) in the form of asfotase alfa to decrease the severity of oral manifestations in children with hypophosphatasia (HPP). Six databases were searched using keywords and index terms related to "hypophosphatasia," "children," and "enzyme replacement therapy." Duplicates were removed and two independent reviewers screened the titles and abstracts to identify articles for full-text review. Extracted data was summarised narratively. The systematic search identified 3548 articles, with 171 suitable for full-text review and a final 22 that met inclusion criteria. Enzyme replacement therapy generally resulted in a reduction in the presence and severity of oral manifestations of HPP. However, numerous studies failed to report specific details regarding the nature of oral health outcomes and there were reported cases of further loss of primary teeth. The available evidence suggests that that ERT in the form of asfotase alfa for HPP in infants and young children leads to improved oral health outcomes. It is recommended that the outcomes are improved with earlier initiation of ERT. Further, well-designed clinical research is required to assess oral health improvements and decreased morbidity associated with the early loss of teeth.
Identifiants
pubmed: 37036643
doi: 10.1007/s40368-023-00796-0
pii: 10.1007/s40368-023-00796-0
doi:
Types de publication
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
429-440Informations de copyright
© 2023. The Author(s), under exclusive licence to European Academy of Paediatric Dentistry.
Références
Anbarserri NM, Ismail KM, Anbarserri H, Alanazi D, AlSaffan AD, Baseer MA, Shaheen R. Impact of severity of tooth loss on oral-health-related quality of life among dental patients. J Fam Med Prim Care. 2020;9(1):187.
doi: 10.4103/jfmpc.jfmpc_909_19
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.
doi: 10.1080/1364557032000119616
Bowden SA, Foster BL. Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy. Drug Des Dev Ther. 2018;12:3147.
doi: 10.2147/DDDT.S154922
European Union Clinical Trials Register. A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Adolescents and Adults with Hypophosphatasia (HPP). EU Clinical Trials Register. 2018.
Faser D. Hypophosphatasie. Am J Med. 1957;22:730–46.
doi: 10.1016/0002-9343(57)90124-9
Feeney C, Stanford N, Lee S, Barry S. Hypophosphatasia and the importance of the general dental practitioner–a case series and discussion of upcoming treatments. Br Dent J. 2018;224(12):937–43.
pubmed: 29999027
doi: 10.1038/sj.bdj.2018.441
Foster ED, Deardorff A. Open Science Framework (OSF). J Med Libr Assoc: JMLA. 2017;105(2):203–6.
pmcid: 5370619
doi: 10.5195/jmla.2017.88
Foster B, Kuss P, Yadav M, Kolli T, Narisawa S, Lukashova L, Cory E, Sah R, Somerman M, Millán J. Conditional Alpl ablation phenocopies dental defects of hypophosphatasia. J Dent Res. 2017;96(1):81–91.
pubmed: 27582029
doi: 10.1177/0022034516663633
Gerritsen AE, Allen PF, Witter DJ, Bronkhorst EM, Creugers NH. Tooth loss and oral health-related quality of life: a systematic review and meta-analysis. Health Qual Life Outcomes. 2010;8(1):1–11.
doi: 10.1186/1477-7525-8-126
Hofmann C, Girschick H, Mentrup B, Graser S, Seefried L, Liese J, Jakob F. Clinical aspects of hypophosphatasia: an update. Clin Rev Bone Miner Metab. 2013;11(2):60–70.
doi: 10.1007/s12018-013-9139-0
Hofmann CE, Harmatz P, Vockley J, Högler W, Nakayama H, Bishop N, Martos-Moreno GA, Moseley S, Fujita KP, Liese J. Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study. J Clin Endocrinol Metab. 2019;104(7):2735–47.
pubmed: 30811537
pmcid: 6530655
doi: 10.1210/jc.2018-02335
Khan A, Josse R, Kannu P, Villeneuve J, Paul T, Van Uum S, Greenberg C. Hypophosphatasia: Canadian update on diagnosis and management. Osteoporos Int. 2019;30(9):1713–22.
pubmed: 30915507
doi: 10.1007/s00198-019-04921-y
Kiselnikova L, Vislobokova E, Voinova V. Dental manifestations of hypophosphatasia in children and the effects of enzyme replacement therapy on dental status: a series of clinical cases. Clin Case Rep. 2020;8(5):911–8.
pubmed: 32477544
pmcid: 7250965
doi: 10.1002/ccr3.2769
Kishnani PS, Rockman-Greenberg C, Denker AE, Moseley S, Whyte MP. Biochemical and physical function outcomes after 5 years of treatment with asfotase alfa in adolescents and adults with hypophosphatasia: phase 2 study results. Bone Abstr. 2017. https://doi.org/10.1530/boneabs.6.OC25 .
doi: 10.1530/boneabs.6.OC25
Kosnik-Infinger L, Gendron C, Gordon CB, Pan BS, van Aalst JA, Vogel TW. Enzyme replacement therapy for congenital hypophosphatasia allows for surgical treatment of related complex craniosynostosis: a case series. Neurosurg Focus. 2015;38(5):E10.
pubmed: 25929963
doi: 10.3171/2015.2.FOCUS14847
Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5(1):69.
pubmed: 20854677
pmcid: 2954944
doi: 10.1186/1748-5908-5-69
Liu M, Liu M, Liang X, Wu D, Li W, Su C, Cao B, Chen J, Gong C. Clinical and genetic characteristics of hypophosphatasia in Chinese children. Orphanet J Rare Dis. 2021;16(1):1–13.
doi: 10.1186/s13023-021-01798-1
Mikelis F, Koletsi D. Scoping reviews in orthodontics: are they justified? Prog Orthod. 2022;23(1):48.
pubmed: 36567358
pmcid: 9790814
doi: 10.1186/s40510-022-00442-3
Millán JL, Plotkin H. Hypophosphatasia-pathophysiology and treatment. Actual Osteol. 2012;8(3):164.
pubmed: 25254037
pmcid: 4171060
Millán JL, Whyte MP. Alkaline phosphatase and hypophosphatasia. Calcif Tissue Int. 2016;98(4):398–416.
pubmed: 26590809
doi: 10.1007/s00223-015-0079-1
Mori M, DeArmey SL, Weber TJ, Kishnani PS. Case series: odontohypophosphatasia or missed diagnosis of childhood/adult-onset hypophosphatasia?–Call for a long-term follow-up of premature loss of primary teeth. Bone Rep. 2016;5:228–32.
pubmed: 28580391
pmcid: 5440952
doi: 10.1016/j.bonr.2016.08.004
Mornet E. Molecular genetics of hypophosphatasia and phenotype-genotype correlations. In: Neuronal Tissue-Nonspecific Alkaline Phosphatase (TNAP). Dordrecht: Springer; 2015. p. 25–43.
doi: 10.1007/978-94-017-7197-9_2
Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018a;18(1):143.
pubmed: 30453902
pmcid: 6245623
doi: 10.1186/s12874-018-0611-x
Munn Z, Stern C, Aromataris E, Lockwood C, Jordan Z. What kind of systematic review should I conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences. BMC Med Res Methodol. 2018b;18(1):5.
pubmed: 29316881
pmcid: 5761190
doi: 10.1186/s12874-017-0468-4
Nadelman P, Magno MB, Pithon MM, de Castro ACR, Maia LC. Does the premature loss of primary anterior teeth cause morphological, functional and psychosocial consequences? Braz Oral Res. 2021. https://doi.org/10.1590/1807-3107bor-2021.vol35.0092 .
doi: 10.1590/1807-3107bor-2021.vol35.0092
pubmed: 34816892
Okawa R, Nakano K, Matsumoto M, Kawabata K, Ooshima T. Oral manifestations of patients with hypophosphatasia. Pediatr Dent J. 2012;22(2):155–62.
doi: 10.1016/S0917-2394(12)70266-5
Okawa R, Kokomoto K, Yamamura-Miyazaki N, Michigami T, Nakano K. Oral findings in patient with lethal hypophosphatasia treated with enzyme replacement therapy. Pediatr Dent J. 2017;27(3):153–6.
doi: 10.1016/j.pdj.2017.04.002
Okawa R, Miura J, Kokomoto K, Nakano K. Evaluation of avulsed primary incisor in 3-year-old girl with hypophosphatasia who received enzyme replacement therapy. Pediatr Dent J. 2018;28(3):136–40.
doi: 10.1016/j.pdj.2018.07.001
Okawa R, Kokomoto K, Kitaoka T, Kubota T, Watanabe A, Taketani T, Michigami T, Ozono K, Nakano K. Japanese nationwide survey of hypophosphatasia reveals prominent differences in genetic and dental findings between odonto and non-odonto types. PLoS ONE. 2019;14(10): e0222931.
pubmed: 31600233
pmcid: 6786601
doi: 10.1371/journal.pone.0222931
Okawa R, Matayoshi S, Kariya R, Ogaya Y, Nomura R, Nakano K. Effects of enzyme replacement therapy for primary teeth in a patient with infantile hypophosphatasia. J Clin Pediatr Dent. 2020;44(5):348–51.
pubmed: 33181846
doi: 10.17796/1053-4625-44.5.9
Okawa R, Kokomoto K, Nakano K. Dental effects of enzyme replacement therapy in case of childhood-type hypophosphatasia. BMC Oral Health. 2021;21(1):1–8.
doi: 10.1186/s12903-021-01673-2
Padidela R. Asfotase alfa treatment in perinatal and infantile hypophosphatasia: safe and sustained efficacy. Lancet Diabetes Endocrinol. 2019;7(2):76–8.
pubmed: 30558908
doi: 10.1016/S2213-8587(18)30321-8
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):1–11.
doi: 10.1186/s13643-021-01626-4
Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC and Khalil H. Chapter 11: Scoping Reviews (2020 version). JBI Manual for Evidence Synthesis. Aromataris E and M. Z. Adelaide, JBI, 2020.
Pimstone B, Eisenberg E, Silverman S. Hypophosphatasia: genetic and dental studies. Ann Intern Med. 1966;65(4):722–9.
pubmed: 4288761
doi: 10.7326/0003-4819-65-4-722
Reibel A, Manière MC, Clauss F, Droz D, Alembik Y, Mornet E, Bloch-Zupan A. Orodental phenotype and genotype findings in all subtypes of hypophosphatasia. Orphanet J Rare Dis. 2009;4(1):1–10.
doi: 10.1186/1750-1172-4-6
Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev: PER. 2013;10:380–8.
pubmed: 23858621
Rodrigues T, Georgetti AP, Martins L, Pereira Neto JS, Foster BL, Nociti FH Jr. Clinical correlate: case study of identical twins with cementum and periodontal defects resulting from odontohypophosphatasia. In: Mineralized tissues in oral and craniofacial science: biological principles and clinical correlates. Ames: Wiley-Blackwell; 2012. p. 183–90.
Schroth RJ, Long C, Lee VH, Alai-Towfigh H, Rockman-Greenberg C. Dental outcomes for children receiving asfotase alfa for hypophosphatasia. Bone. 2021;152: 116089.
pubmed: 34175501
doi: 10.1016/j.bone.2021.116089
Strandbech OS, Lund A, Ostergaard E. Excellent response to asfotase alfa treatment in an adolescent patient with hypophosphatasia. JIMD Reports. 2021;59(1):10–5.
pubmed: 33977024
pmcid: 8100395
doi: 10.1002/jmd2.12198
Takagi M, Kato S, Muto T, Sano Y, Akiyama T, Takagi J, Okumura A, Iwayama H. Odontohypophosphatasia treated with asfotase alfa enzyme replacement therapy in a toddler: a case report. Clin Pediatr Endocrinol. 2020;29(3):115–8.
pubmed: 32694888
pmcid: 7348629
doi: 10.1297/cpe.29.115
United States National Library of Medicine ClinicalTrials.gov. Study of Asfotase Alfa in Children With Hypophosphatasia (HPP). U.S. National Library of Medicine ClinicalTrials.gov. 2019.
Wang Z, Zhang K, Zheng G, Qiao W, Su Y. Current concepts in odontohypophosphatasia form of hypophosphatasia and report of two cases. BMC Oral Health. 2016;16(1):1–8.
doi: 10.1186/s12903-016-0266-0
Whyte MP. Hypophosphatasia: enzyme replacement therapy brings new opportunities and new challenges. J Bone Miner Res. 2017;32(4):667–75.
pubmed: 28084648
doi: 10.1002/jbmr.3075
Whyte MP, Teitelbaum SL, Murphy WA, Bergfeld MA, Avioli LV. Adult hypophosphatasia. Clinical, laboratory, and genetic investigation of a large kindred with review of the literature. Medicine. 1979;58(5):329–47.
pubmed: 481194
doi: 10.1097/00005792-197909000-00001
Whyte MP, Valdes R Jr, Ryan LM, McAlister WH. Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. J Pediatr. 1982;101(3):379–86.
pubmed: 7108657
doi: 10.1016/S0022-3476(82)80061-9
Whyte MP, Mahuren J, Fedde K, Cole F, McCabe E, Coburn S. Perinatal hypophosphatasia: tissue levels of vitamin B6 are unremarkable despite markedly increased circulating concentrations of pyridoxal-5’-phosphate. Evidence for an ectoenzyme role for tissue-nonspecific alkaline phosphatase. J Clin Invest. 1988;81(4):1234–9.
pubmed: 3350970
pmcid: 329654
doi: 10.1172/JCI113440
Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366(10):904–13.
pubmed: 22397652
doi: 10.1056/NEJMoa1106173
Whyte MP, Leelawattana R, Reinus WR, Yang C, Mumm S, Novack DV. Acute severe hypercalcemia after traumatic fractures and immobilization in hypophosphatasia complicated by chronic renal failure. J Clin Endocrinol Metab. 2013;98(12):4606–12.
pubmed: 24064686
pmcid: 6287393
doi: 10.1210/jc.2013-1811
Whyte MP, Simmons JH, Moseley S, Fujita KP, Bishop N, Salman NJ, Taylor J, Phillips D, McGinn M, McAlister WH. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol. 2019;7(2):93–105.
pubmed: 30558909
doi: 10.1016/S2213-8587(18)30307-3
Zauza D, Dotto L, Moher D, Tricco AC, Agostini B, Sarkis-Onofre R. There is room for improvement in the use of scoping reviews in dentistry. J Dent. 2022;122:104161.
pubmed: 35577253
doi: 10.1016/j.jdent.2022.104161